Cosibelimab for Skin Cancer

This trial tests cosibelimab, an anti-PD-L1 antibody, to evaluate its safety and effectiveness in treating advanced cutaneous squamous cell carcinoma (CSCC). Participants fall into two groups: one group includes kidney transplant recipients who will receive cosibelimab alongside their regular immune-suppressing medication, while the other group consists of individuals with blood cancers and CSCC who will receive only cosibelimab. The trial seeks participants with CSCC advanced enough that surgery or radiation is no longer viable, including those with a kidney transplant or specific blood cancers. Individuals with advanced skin cancer and a history of kidney transplant or certain blood cancers may be suitable for this study. As a Phase 4 trial, cosibelimab has already received FDA approval and proven effective, and this research aims to understand its benefits for more patients.

The trial does not specify if you need to stop taking your current medications. However, if you are on systemic steroids, certain cancer treatments, or investigational agents, you may need to stop or adjust them. It's best to discuss your specific medications with the trial team.

Research has shown that cosibelimab, a type of medication, has been studied for its safety and effectiveness in treating advanced skin cancer called cutaneous squamous cell carcinoma (CSCC). Results indicate that patients generally tolerate it well. Studies have found that cosibelimab rarely causes serious immune system problems, meaning most people do not experience severe immune-related side effects.

Furthermore, some studies reported no extremely severe immune-related side effects, suggesting that the most serious reactions are uncommon. The side effects of cosibelimab are usually manageable, meaning they can often be controlled or treated without much difficulty.

Researchers are excited about Cosibelimab because it offers a novel approach to treating advanced cutaneous squamous cell carcinoma (CSCC). Unlike the standard of care, which often includes chemotherapy and radiation, Cosibelimab is an immunotherapy that targets the PD-1/PD-L1 pathway, enhancing the body's immune response against cancer cells. This targeted mechanism is promising as it could lead to fewer side effects and potentially better outcomes in patients who have not responded well to traditional treatments. Additionally, for kidney transplant recipients with advanced CSCC, Cosibelimab is being tested in combination with an immunosuppressive regimen, which is a unique approach that aims to balance cancer treatment with the prevention of transplant rejection.

Research shows that cosibelimab effectively treats advanced cutaneous squamous cell carcinoma (CSCC). In this trial, participants in Cohort A will receive Cosibelimab with a standard immunosuppressive regimen, while those in Cohort B will receive Cosibelimab alone. Studies have found that cosibelimab has a strong success rate, with about 47% of patients responding positively to the treatment. Additionally, cases where the cancer completely disappears have increased. After 24 months, the survival rate was high: 72.1% for patients with metastatic CSCC and 80.2% for those with locally advanced CSCC. Importantly, cosibelimab is generally safe, with low rates of serious immune-related side effects. This evidence suggests that cosibelimab is a promising option for people with advanced CSCC.¹³⁴⁶⁷